esophagogastric junction

Summary

Summary: The area covering the terminal portion of ESOPHAGUS and the beginning of STOMACH at the cardiac orifice.

Top Publications

  1. Reim D, Gertler R, Novotny A, Becker K, Zum Büschenfelde C, Ebert M, et al. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer. Ann Surg Oncol. 2012;19:2108-18 pubmed publisher
    Preoperative chemotherapy has been shown to improve outcome of patients with adenocarcinoma of the esophagogastric junction (AEG) and gastric cancer (GC), and histopathologic response has been identified as an independent prognostic ..
  2. Imai K, Kakushima N, Tanaka M, Takizawa K, Matsubayashi H, Hotta K, et al. Validation of the application of the Japanese curative criteria for superficial adenocarcinoma at the esophagogastric junction treated by endoscopic submucosal dissection: a long-term analysis. Surg Endosc. 2013;27:2436-45 pubmed publisher
    ..have shown promising results with endoscopic submucosal dissection (ESD) for adenocarcinoma at the esophagogastric junction (EGJAC)...
  3. Grotenhuis B, Wijnhoven B, Poley J, Hermans J, Biermann K, Spaander M, et al. Preoperative assessment of tumor location and station-specific lymph node status in patients with adenocarcinoma of the gastroesophageal junction. World J Surg. 2013;37:147-55 pubmed publisher
  4. Ren M, Huang B, Zhang J, Pu M, Deng S. [Laparoscopic transhiatal proximal gastrectomy for adenocarcinoma of the esophagogastric junction: report of 98 cases]. Zhonghua Wei Chang Wai Ke Za Zhi. 2012;15:906-9 pubmed
    To explore the safety and short-term efficacy of laparoscopic transhiatal proximal gastrectomy in patients with adenocarcinoma of the esophagogastric junction.
  5. Gertler R, Stein H, Loos M, Langer R, Friess H, Feith M. How to classify adenocarcinomas of the esophagogastric junction: as esophageal or gastric cancer?. Am J Surg Pathol. 2011;35:1512-22 pubmed publisher
    To evaluate whether so-called cardiac adenocarcinomas (adenocarcinomas of the esophagogastric junction type II and III, ie AEG II and III) are better staged as cancers of the esophagus or as cancers of the stomach.
  6. Sakamoto Y, Sakaguchi Y, Akimoto H, Chinen Y, Kojo M, Sugiyama M, et al. Safe laparoscopic resection of a gastric gastrointestinal stromal tumor close to the esophagogastric junction. Surg Today. 2012;42:708-11 pubmed publisher
    ..gastric function; however, performing a wedge resection to excise a large tumor located close to the esophagogastric junction (EGJ) can result in deformation of the stomach and/or the stenosis of the EGJ if the gastric wall ..
  7. Biere S, van Berge Henegouwen M, Maas K, Bonavina L, Rosman C, Garcia J, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 2012;379:1887-92 pubmed publisher
    ..We assessed whether minimally invasive oesophagectomy reduces morbidity compared with open oesophagectomy...
  8. Rohof W, Hirsch D, Kessing B, Boeckxstaens G. Efficacy of treatment for patients with achalasia depends on the distensibility of the esophagogastric junction. Gastroenterology. 2012;143:328-35 pubmed publisher
    ..Distensibility of the esophagogastric junction (EGJ) largely determines esophageal emptying...
  9. Kakeji Y, Yamamoto M, Ito S, Sugiyama M, Egashira A, Saeki H, et al. Lymph node metastasis from cancer of the esophagogastric junction, and determination of the appropriate nodal dissection. Surg Today. 2012;42:351-8 pubmed publisher
    Both squamous cell carcinomas and adenocarcinomas can develop in the esophagogastric junction. To clarify the appropriate lymph node dissection range, lymph node metastases from cancers in the esophagogastric junction were investigated.

More Information

Publications62

  1. Yamashita H, Katai H, Morita S, Saka M, Taniguchi H, Fukagawa T. Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma. Ann Surg. 2011;254:274-80 pubmed publisher
    To determine the optimal extent of lymph node dissection for carcinomas of the true cardia, otherwise called Siewert type II esophagogastric junction (EGJ) carcinomas.
  2. Kim H, Cheong J, Song K, An J, Hyung W, Noh S, et al. Staging of adenocarcinoma of the esophagogastric junction: comparison of AJCC 6th and 7th gastric and 7th esophageal staging systems. Ann Surg Oncol. 2013;20:2713-20 pubmed publisher
    Adenocarcinoma of esophagogastric junction (EGJ) is currently staged by the esophageal staging criteria according to the American Joint Committee on Cancer (AJCC) staging system, 7th edition...
  3. Hosokawa Y, Kinoshita T, Konishi M, Takahashi S, Gotohda N, Kato Y, et al. Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan. Ann Surg Oncol. 2012;19:677-83 pubmed publisher
    Treatment strategy for adenocarcinoma of the esophagogastric junction (AEG) remains controversial...
  4. Xu X, Chen K, Zhou W, Zhang R, Wang J, Wu D, et al. Laparoscopic transgastric resection of gastric submucosal tumors located near the esophagogastric junction. J Gastrointest Surg. 2013;17:1570-5 pubmed publisher
    ..But it cannot easily be applied to tumors located near the esophagogastric junction (EGJ) due to the high risk of causing deformity or stenosis in the gastric inlet...
  5. Kurokawa Y, Sasako M, Doki Y. Treatment approaches to esophagogastric junction tumors. Dig Surg. 2013;30:169-73 pubmed publisher
    b>Esophagogastric junction (EGJ) adenocarcinomas are usually classified into one of the three categories of the Siewert system. The clinicopathological features of EGJ adenocarcinomas vary according to this classification scheme...
  6. Matuschek C, Bölke E, Peiper M, Knoefel W, Budach W, Erhardt A, et al. The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract. Eur J Med Res. 2011;16:265-74 pubmed
    ..In addition, there are no standard recommendations for adjuvant chemotherapy or chemoradiation after R0 resection and adequate lymph node dissection...
  7. Liao L, Vaughan T, Corley D, Cook M, Casson A, Kamangar F, et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology. 2012;142:442-452.e5; quiz e22-3 pubmed publisher
    ..causation could, in part, explain the inverse association observed between NSAID use and EAC risk, our pooled analysis suggests a possible role for NSAIDs in prevention of adenocarcinomas of the esophagus and esophagogastric junction.
  8. Oshima T, Masuda M. Molecular targeted agents for gastric and gastroesophageal junction cancer. Surg Today. 2012;42:313-27 pubmed publisher
    ..In this review we focus on the recent developments in targeting relevant pathways in these types of cancer...
  9. Wang W, Wang K, Gao Q, Chen L. Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction. World J Surg Oncol. 2012;10:14 pubmed publisher
    ..The aim of this study was to investigate the existence of EGFR mutations in carcinoma of esophagogastric junction, and also to explore the possibility of treating carcinoma of esophagogastric junction using gefitinib.
  10. Bekkar S, Gronnier C, Messager M, Robb W, Piessen G, Mariette C. The impact of preoperative radiochemotherapy on survival in advanced esophagogastric junction signet ring cell adenocarcinoma. Ann Thorac Surg. 2014;97:303-10 pubmed publisher
    ..Preoperative radiochemotherapy, of already proven efficacy for esophagogastric junction adenocarcinomas (EGJA), could be an alternative neoadjuvant strategy for SRC EGJA...
  11. Phillips B, Tubbs R, Rice T, Rybicki L, Plesec T, Rodriguez C, et al. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction. Dis Esophagus. 2013;26:299-304 pubmed publisher
    ..Given the demonstrated benefit of trastuzumab in HER2-positive gastric cancer and the similar incidence of HER2 overexpression in esophageal/GEJ adenocarcinoma, further evaluation of HER2-directed therapy in this disease seems indicated...
  12. Omae M, Fujisaki J, Horiuchi Y, Yoshizawa N, Matsuo Y, Kubota M, et al. Safety, efficacy, and long-term outcomes for endoscopic submucosal dissection of early esophagogastric junction cancer. Gastric Cancer. 2013;16:147-54 pubmed publisher
    Early esophagogastric junction (EGJ) cancer is currently being treated in the same way as early gastric cancer, by endoscopic submucosal dissection (ESD), but long-term outcomes are still unknown...
  13. Reeh M, Mina S, Bockhorn M, Kutup A, Nentwich M, Marx A, et al. Staging and outcome depending on surgical treatment in adenocarcinomas of the oesophagogastric junction. Br J Surg. 2012;99:1406-14 pubmed publisher
    ..In a retrospective study, preoperative staging of AOG and the impact of preoperative misclassification on outcome were analysed...
  14. Kole T, Aghayere O, Kwah J, Yorke E, Goodman K. Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys. 2012;83:1580-6 pubmed publisher
    ..four-field three-dimensional conformal radiotherapy (3D-CRT) treatment plans for patients with distal esophageal cancer undergoing chemoradiation...
  15. Li Q, Yao L, Zhou P, Xu M, Chen S, Zhong Y, et al. Submucosal tumors of the esophagogastric junction originating from the muscularis propria layer: a large study of endoscopic submucosal dissection (with video). Gastrointest Endosc. 2012;75:1153-8 pubmed publisher
    ..a minor invasive treatment without loss of curability is desirable for submucosal tumors (SMTs) of the esophagogastric junction (EGJ)...
  16. Hechtman J, Polydorides A. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med. 2012;136:691-7 pubmed publisher
    ..Here, we briefly review the molecular biology, histopathology, diagnostic techniques, and interpretation, as well as the clinical implications, of HER2 amplification/overexpression in gastric and gastroesophageal adenocarcinoma...
  17. van Hagen P, Hulshof M, van Lanschot J, Steyerberg E, van Berge Henegouwen M, Wijnhoven B, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074-84 pubmed publisher
    ..We compared chemoradiotherapy followed by surgery with surgery alone in this patient population...
  18. Hara J, Nakajima K, Takahashi T, Yamasaki M, Miyata H, Kurokawa Y, et al. Laparoscopic intragastric surgery revisited: its role for submucosal tumors adjacent to the esophagogastric junction. Surg Laparosc Endosc Percutan Tech. 2012;22:251-4 pubmed publisher
    When the gastric submucosal tumor (SMT) locates adjacent to the esophagogastric junction (EGJ), it is difficult to preserve EGJ technically and oncologically...
  19. Zhang Y, Shi J, Yu H, Feng A, Fan X, Lauwers G, et al. Factors predicting survival in patients with proximal gastric carcinoma involving the esophagus. World J Gastroenterol. 2012;18:3602-9 pubmed publisher
    ..To investigate the clinicopathologic features which predict surgical overall survival in patients with proximal gastric carcinoma involving the esophagus (PGCE)...
  20. Shan L, Ying J, Lu N. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. Diagn Pathol. 2013;8:76 pubmed publisher
    ..In this study, the frequency of HER2 expression and the relationship between HER2 expression and clinicopathological features were examined in a large cohort of Chinese GC and GEJ cancer patients...
  21. Ford H, Marshall A, Bridgewater J, Janowitz T, Coxon F, Wadsley J, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014;15:78-86 pubmed publisher
    ..We assessed whether the addition of docetaxel to active symptom control alone can improve survival and HRQoL for patients...
  22. Zum Büschenfelde C, Herrmann K, Schuster T, Geinitz H, Langer R, Becker K, et al. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med. 2011;52:1189-96 pubmed publisher
    ..Therefore, we initiated this prospective trial to improve the clinical outcome of metabolic nonresponders using a salvage neoadjuvant radiochemotherapy...
  23. Tafe L, Janjigian Y, Zaidinski M, Hedvat C, Hameed M, Tang L, et al. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization. Arch Pathol Lab Med. 2011;135:1460-5 pubmed publisher
    ..Patients with advanced gastroesophageal cancer have poor survival with current therapy. Human epidermal growth factor receptor 2 (HER2) represents a promising therapeutic target, but the optimal HER2 testing strategy is not yet defined...
  24. Lorenzen S, von Gall C, Stange A, Haag G, Weitz J, Haberkorn U, et al. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial. BMC Cancer. 2011;11:266 pubmed publisher
    ..We plan to investigate whether PET can be used as response assessment during radiochemotherapy given as salvage treatment in early metabolic non-responders to standard chemotherapy...
  25. Ruschoff J, Hanna W, Bilous M, Hofmann M, Osamura R, Penault Llorca F, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25:637-50 pubmed publisher
    ..It is anticipated that these recommendations should ensure accurate and consistent HER2 testing, which will allow appropriate selection of patients eligible for treatment with trastuzumab...
  26. Gurzu S, Szentirmay Z, Turcu M, Toth E, Bara T, Jung I. Non-Epstein-Barr virus associated lymphoepithelioma-like carcinoma of the esophagogastric junction with microsatellite instability, K-ras wild type. Pathol Res Pract. 2013;209:128-31 pubmed publisher
    ..Macroscopically, a 45 mm × 20 mm × 10 mm-sized, ulcero-infiltrative tumor located in the esophagogastric junction was described...
  27. Janjigian Y, Werner D, Pauligk C, Steinmetz K, Kelsen D, Jager E, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012;23:2656-62 pubmed
    ..To determine whether human epidermal growth factor receptor 2 (HER2) status is an independent prognostic factor in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma...
  28. Suh Y, Han D, Kong S, Lee H, Kim Y, Kim W, et al. Should adenocarcinoma of the esophagogastric junction be classified as esophageal cancer? A comparative analysis according to the seventh AJCC TNM classification. Ann Surg. 2012;255:908-15 pubmed publisher
    The aim of this study was to evaluate the adequacy of esophageal classification for adenocarcinoma of the esophagogastric junction (AEJ) of the seventh American Joint Committee on Cancer (AJCC) TNM classification.
  29. Nakamura M, Iwahashi M, Nakamori M, Naka T, Ojima T, Iida T, et al. Lower mediastinal lymph node metastasis is an independent survival factor of Siewert type II and III adenocarcinomas in the gastroesophageal junction. Am Surg. 2012;78:567-73 pubmed
    ..Therefore, the preoperative early detection of such metastasis is important to improve patient survival...
  30. De Hertogh G, Van Eyken P, Ectors N, Geboes K. On the origin of cardiac mucosa: a histological and immunohistochemical study of cytokeratin expression patterns in the developing esophagogastric junction region and stomach. World J Gastroenterol. 2005;11:4490-6 pubmed
    To examine the fetal and neonatal esophagogastric junction region (EGJ) histologically for the presence of an equivalent to adult cardiac mucosa (CM); to study the expression patterns of all cytokeratins (CK) relevant to the EGJ during ..
  31. Chang A, Ji H, Birkmeyer N, Orringer M, Birkmeyer J. Outcomes after transhiatal and transthoracic esophagectomy for cancer. Ann Thorac Surg. 2008;85:424-9 pubmed publisher
    ..This study was performed to determine outcomes after transhiatal and transthoracic esophagectomy for patients undergoing resection nationwide...
  32. Al Batran S, Hartmann J, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1435-42 pubmed publisher
    ..This study was designed to compare fluorouracil, leucovorin, and oxaliplatin with fluorouracil, leucovorin, and cisplatin in patients with advanced gastric cancer...
  33. Takubo K, Vieth M, Aida J, Sawabe M, Kumagai Y, Hoshihara Y, et al. Differences in the definitions used for esophageal and gastric diseases in different countries: endoscopic definition of the esophagogastric junction, the precursor of Barrett's adenocarcinoma, the definition of Barrett's esophagus, and histologic cr. Digestion. 2009;80:248-57 pubmed publisher
    ..Definitions and opinions in the field of gastroenterology vary widely in different countries...
  34. Rice T, Rusch V, Ishwaran H, Blackstone E. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer. 2010;116:3763-73 pubmed publisher
    ..At the request of the AJCC, worldwide data from 3 continents were assembled to develop data-driven, harmonized esophageal staging for the seventh edition of the AJCC/UICC cancer staging manuals...
  35. Sendler A. Metabolic response evaluation by PET during neoadjuvant treatment for adenocarcinoma of the esophagus and esophagogastric junction. Recent Results Cancer Res. 2010;182:167-77 pubmed publisher
    Following several randomized trials, neoadjuvant therapy in adenocarcinoma of esophagus and the esophagogastric junction can be seen as an international standard...
  36. Kwiatek M, Pandolfino J, Kahrilas P. 3D-high resolution manometry of the esophagogastric junction. Neurogastroenterol Motil. 2011;23:e461-9 pubmed publisher
    The esophagogastric junction (EGJ) is a complex structure that challenges accurate manometric recording...
  37. Cook M, Kamangar F, Whiteman D, Freedman N, Gammon M, Bernstein L, et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst. 2010;102:1344-53 pubmed publisher
    Previous studies that showed an association between smoking and adenocarcinomas of the esophagus and esophagogastric junction were limited in their ability to assess differences by tumor site, sex, dose-response, and duration of cigarette ..
  38. Hoppo T, McMahon B, Witteman B, Kraemer S, O Rourke R, Gravesen F, et al. Functional lumen imaging probe to assess geometric changes in the esophagogastric junction following endolumenal fundoplication. J Gastrointest Surg. 2011;15:1112-20 pubmed publisher
  39. Gu Y, Swisher S, Ajani J, Correa A, Hofstetter W, Liao Z, et al. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer. 2006;106:1017-25 pubmed
    The survival of patients with locoregional adenocarcinoma of the esophagus or the esophagogastric junction (EGJ) who receive preoperative chemoradiation is reported to be better among patients who achieve a pathologic complete response ..
  40. Dupont J, Jensen H, Jensen B, Pfeiffer P. Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer. Acta Oncol. 2007;46:330-5 pubmed
  41. Boyer J, Laugier R, Chemali M, Arpurt J, Boustiere C, Canard J, et al. French Society of Digestive Endoscopy SFED guideline: monitoring of patients with Barrett's esophagus. Endoscopy. 2007;39:840-2 pubmed
  42. Demicco E, Farris A, Baba Y, Agbor Etang B, Bergethon K, Mandal R, et al. The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type vs cardiac-type mucosa-associated adenocarcinoma. Mod Pathol. 2011;24:1177-90 pubmed publisher
    Adenocarcinoma of the distal esophagus and esophagogastric junction continues to rise in incidence. An intestinal metaplasia (Barrett esophagus)-dysplasia-carcinoma sequence induced by gastroesophageal reflux disease is well established...
  43. Wijetunge S, Ma Y, DeMeester S, Hagen J, Demeester T, Chandrasoma P. Association of adenocarcinomas of the distal esophagus, "gastroesophageal junction," and "gastric cardia" with gastric pathology. Am J Surg Pathol. 2010;34:1521-7 pubmed publisher
    ..This suggests that the reflux of the gastric juice whose composition has been altered by gastritis and H. pylori infection may be associated with an increased tendency to HGD and/or adenocarcinoma in the distal third of the esophagus...
  44. Ott K, Bader F, Lordick F, Feith M, Bartels H, Siewert J. Surgical factors influence the outcome after Ivor-Lewis esophagectomy with intrathoracic anastomosis for adenocarcinoma of the esophagogastric junction: a consecutive series of 240 patients at an experienced center. Ann Surg Oncol. 2009;16:1017-25 pubmed publisher
    ..number of randomized studies, the surgical approach to locally advanced adenocarcinoma of the esophagogastric junction (AEG) I and II is still discussed controversially...
  45. Moehler M, Kanzler S, Geissler M, Raedle J, Ebert M, Daum S, et al. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2010;21:71-7 pubmed publisher
    ..This randomized phase II trial compared for the first time capecitabine with irinotecan or cisplatin in this setting...
  46. Dutta S, Crumley A, Fullarton G, Horgan P, McMillan D. Comparison of the prognostic value of tumour- and patient-related factors in patients undergoing potentially curative resection of oesophageal cancer. World J Surg. 2011;35:1861-6 pubmed publisher
    ..The aim of the present study was to compare the predictive value of selected markers of systemic inflammation in patients who undergo surgical resection of oesophageal cancer...
  47. Abraham S, Krasinskas A, Hofstetter W, Swisher S, Wu T. "Seedling" mesenchymal tumors (gastrointestinal stromal tumors and leiomyomas) are common incidental tumors of the esophagogastric junction. Am J Surg Pathol. 2007;31:1629-35 pubmed
    ..However, the prevalence and characteristics of small GISTs in surgical resections of the esophagogastric junction (EGJ) remains unclear...
  48. Noar M, Noar E. Gastroparesis associated with gastroesophageal reflux disease and corresponding reflux symptoms may be corrected by radiofrequency ablation of the cardia and esophagogastric junction. Surg Endosc. 2008;22:2440-4 pubmed publisher
    ..Radiofrequency treatment for GERD potentially corrects GERD-associated gastroparesis and resultant PPI BID reflux failures...
  49. Wang K, Wu T, Choi I, Wang H, Resetkova E, Reseetkova E, et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer. 2007;109:658-67 pubmed
    The prognosis for patients with esophageal and esophagogastric junction (EGJ) adenocarcinoma remains poor, even after surgical resection...
  50. von Rahden B, Stein H, Siewert J. Surgical management of esophagogastric junction tumors. World J Gastroenterol. 2006;12:6608-13 pubmed
    Surgical resection with lymphadenectomy is the mainstay of treatment for all resectable esophagogastric junction tumors, prior to systemic generalization of the disease...
  51. Cunningham D, Allum W, Stenning S, Thompson J, Van De Velde C, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20 pubmed
    ..We assessed whether the addition of a perioperative regimen of ECF to surgery improves outcomes among patients with potentially curable gastric cancer...
  52. Odemis B, Cicek B, Zengin N, Arhan M, Kacar S, Cengiz C, et al. Barrett's esophagus and endoscopically assessed esophagogastric junction integrity in 1000 consecutive Turkish patients undergoing endoscopy: a prospective study. Dis Esophagus. 2009;22:649-55 pubmed publisher
    ..BE is a complication of gastroesophageal reflux disease (GERD). Anatomical abnormalities of the esophagogastric junction (EGJ) are an important factor in the pathogenesis of GERD...
  53. Bafandeh Y, Esmaili H, Aharizad S. Endoscopic and histologic findings in Iranian patients with heartburn. Indian J Gastroenterol. 2005;24:236-8 pubmed
    ..We looked for endoscopic and histologic evidence of Barrett's esophagus in Iranian patients with heartburn...